CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular...

Area of Science:

• Oncology
• Molecular Biology
• Cellular Biology

Background:

• CDK4/6 inhibitors are standard treatments for metastatic breast cancer, typically combined with endocrine therapy due to limited monotherapy efficacy.
• Understanding the molecular mechanisms of response to CDK4/6 inhibitors is vital for designing improved therapeutic strategies.

Purpose of the Study:

• To elucidate the multi-step molecular mechanism of response to the CDK4/6 inhibitor palbociclib in bladder cancer cells.
• To translate these findings to understand the response in bladder cancer upon PD treatment.

Main Methods:

• Time-course RNA sequencing analysis of bladder cancer cells treated with palbociclib.
• Investigation of protein translocation, proteolysis, and gene expression changes.

Main Results:

• Initial response involves RB protein nuclear translocation via importin α/β and cytoplasmic proteolysis regulated by gankyrin and SCF complex.
• Hypophosphorylated RB accumulation in the nucleus is essential for G1 arrest and therapeutic response, explaining poor outcomes in RB-negative/mutated patients.
• Later stages show increased MiT/TFE family expression, driving lysosomal biogenesis to sustain the response, preceding senescence, apoptosis, or resistance development.

Conclusions:

• The study details a multi-step response mechanism to CDK4/6 inhibition involving RB protein dynamics and lysosomal biogenesis.
• Findings provide insights into therapeutic efficacy and resistance mechanisms, potentially guiding future treatment designs for cancers including breast and bladder cancer.